Great to see 4DX among the Featured Exibitors at the 2024 ATS convention in San Diego with their booth in prime location on the Exhibit Floor as well as conducting two industry presentations highlighting their technical and clinical insights. A big step up from when they were on the peripherey a few years ago.
![]()
4DMedical provides FDA-cleared four-dimensional lung imaging technology, to deliver insights into airflow and regional lung function during a patient’s tidal breath cycle. Our XV Lung Ventilation Analysis Software (XV LVAS) is a first, as an imaging modality that quantitatively measures the regional lung function. A simple protocol using existing hospital fluoroscopy captures X-ray images and then using our proprietary flow velocity measurement technique, XV Technology provides a 4D view of lungs like never before.
![]()
Located right next to some big names in healthcare.
![]()
Two Industry Programs
Sun. May. 19 | 11:55 AM - 12:15 PM – Advances in Ventilation and Perfusion (VQ) Assessment in COPD, CTEPH and Other Chronic Pulmonary Vascular Disorders
Struggling to understand DRRD? This fireside chat, led by renowned patient advocate Rosie Torres and with Dr. Greg Mogel, offers a unique opportunity to hear directly from Veterans battling this complex illness. The session will bridge the gap between science, medicine, policy and the lived experiences of those who have served and often suffer the “hidden wounds of war.”
Veterans will share their experiences with toxic exposure, the challenges of navigating the VA healthcare system for diagnosis, treatment, and benefits all while living with impact of this poorly understood condition. Hear and share updates on the latest developments in diagnosing and managing this complex respiratory condition, including XV Technology (4DMedical), a breakthrough non-invasive alternative to surgical biopsy.
![]()
Mon. May. 20 | 12:15 PM - 12:35 PM – Veterans in Crisis: Uncovering the Realities of Burn Pit Exposure and DRRD
This educational session will review ventilation and perfusion (VQ) mismatch in chronic obstructive pulmonary disease and chronic thromboembolic pulmonary disorders.
Advances in contrast-free ventilation perfusion (CT:VQ), new functional lung imaging technology pending regulatory clearance (4DMedical) for assessing regional lung function by extracting quantitative data using standard inspiratory/expiratory CT scans, eliminating the need for contrast agents.
Preliminary clinical cases will be presented, along with technical and clinical insights into
interpretation and implementation in care.
![]()
- Forums
- ASX - By Stock
- 4DX
- Research
Research, page-2428
-
-
- There are more pages in this discussion • 416 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add 4DX (ASX) to my watchlist
|
|||||
Last
43.0¢ |
Change
-0.010(2.27%) |
Mkt cap ! $176.5M |
Open | High | Low | Value | Volume |
44.5¢ | 45.0¢ | 42.5¢ | $218.0K | 499.4K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 90203 | 43.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
44.0¢ | 4379 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 90203 | 0.430 |
2 | 25232 | 0.425 |
7 | 63449 | 0.420 |
3 | 13257 | 0.415 |
10 | 106573 | 0.410 |
Price($) | Vol. | No. |
---|---|---|
0.440 | 4379 | 2 |
0.445 | 21505 | 1 |
0.450 | 52896 | 5 |
0.455 | 21978 | 1 |
0.460 | 43107 | 4 |
Last trade - 16.10pm 03/09/2024 (20 minute delay) ? |
Featured News
4DX (ASX) Chart |